scholarly journals Erratum: Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

2014 ◽  
Vol 111 (12) ◽  
pp. 2383-2383 ◽  
Author(s):  
A B Suttle ◽  
H A Ball ◽  
M Molimard ◽  
T E Hutson ◽  
C Carpenter ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Clinical Safety ◽  
Safety And Efficacy

scholarly journals Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

2014 ◽  
Vol 111 (10) ◽  
pp. 1909-1916 ◽  
Author(s):  
A B Suttle ◽  
H A Ball ◽  
M Molimard ◽  
T E Hutson ◽  
C Carpenter ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Clinical Safety ◽  
Safety And Efficacy

scholarly journals Nivolumab and Ipilimumab Immunotherapy for Hemodialysis Patients with Advanced Renal Cell Carcinoma

2020 ◽  
Vol 27 (4) ◽  
pp. 225-228
Author(s):  
Y. Kobayashi ◽  
H. Arai ◽  
M. Honda
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Function ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Immune Checkpoint ◽  
Renal Cell ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Advanced Renal Cell Carcinoma ◽  
Safety And Efficacy

Combined immune checkpoint blockade with nivolumab and ipilimumab is standard therapy for the treatment of patients with previously untreated advanced renal cell carcinoma who are at intermediate or poor risk. However, data about the safety and efficacy of combined immune checkpoint blockade with nivolumab and ipilimumab in patients on hemodialysis are limited. Renal function has no known clinically important effects on the pharmacokinetics and clearance of nivolumab and ipilimumab. Further, most immune-related adverse events in patients on hemodialysis are thought to be manageable with the same treatments applied in patients with normal renal function. We present a case of advanced clear-cell renal cell carcinoma in a patient on hemodialysis who received combined immune checkpoint blockade with nivolumab and ipilimumab and who showed no evident signs of immune-related adverse events. Here, we confirm the safety and efficacy of combined immune checkpoint blockade with nivolumab and ipilimumab in a patient on hemodialysis.

Sign in / Sign up

Export Citation Format

Share Document